AXLA Axcella Health

Axcella’s Late-Breaker Data from AXA1125-003 Clinical Study Presented at the EASL Digital International Liver Congress

(Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, announced that data are being presented today in a late-breaker poster regarding key findings from its AXA1125-003 clinical study by Stephen A. Harrison, M.D., Medical Director of Pinnacle Clinical Research in San Antonio, TX, visiting professor of Hepatology at the University of Oxford, UK. The poster presentation is entitled “Multifactorial Effects of AXA1125 and AXA1957 Observed on Markers of Metabolism, Inflammation and Fibrosis: A 16-Week Randomized Placebo-Controlled Study in Subjects With Nonalcoholic Fatty Liver Disease (NAFLD) With and Without Type 2 Diabetes (T2D).”

“Based on the multifactorial effects seen in initial clinical investigations and its well-tolerated profile to date, AXA1125 is among the most intriguing candidates in development for nonalcoholic steatohepatitis (NASH),” said Dr. Harrison. “Notable reductions in virtually all non-invasive biomarkers – including liver fat content (MRI-PDFF), alanine aminotransferase (ALT) and corrected T1 (cT1) – were seen in subjects receiving AXA1125 versus placebo in the 003 clinical study. Interestingly, mean reductions in these measures were even greater among subjects with T2D, providing the potential for a highly differentiated profile within the NASH field.”

AXA1125-003 was a placebo-controlled, randomized, multi-arm clinical study assessing the impact of AXA1125 and AXA1957 on safety, tolerability and effects on structures and functions of the liver. A total of 102 adult subjects with presumed NASH were enrolled and dosed in a 2:2:2:1 ratio to receive AXA1125, one of two AXA1957 doses, or placebo administered twice daily for 16 weeks. Study subjects were stratified based on the presence or absence of T2D, with approximately 40 percent of the subjects having T2D.

Highlights from the presentation include:

  • The AXA1125 study arm consistently achieved numerically greater reductions from baseline in biomarkers of liver fat and fibroinflammation versus placebo, with AXA1957 showing activity in a number of key biomarkers, but with less consistent directional change than AXA1125
  • A reduction from baseline was seen in the AXA1125 arm compared with placebo at weeks 8 and 16 in:
    • Liver fat biomarker MRI-PDFF
    • HOMA-IR
    • ALT
    • CK-18 M65
    • ProC3
    • cT1
  • In the AXA1125 arm, 39 percent of subjects achieved a ≥30 percent relative reduction in MRI-PDFF, 39 percent achieved a ≥17 U/L reduction in ALT from baseline, and 54 percent achieved a ≥40 millisecond absolute reduction in cT1
  • AXA1125 and AXA1957 were both generally well tolerated in the study, with low rates of discontinuations and with all product-emergent adverse events being mild or moderate

, the company plans to advance AXA1125 into a Phase 2b clinical trial in adult NASH in the first half of 2021.

About Endogenous Metabolic Modulators (EMMs)

EMMs are a broad family of molecules, including amino acids, that regulate human metabolism. Axcella is developing a range of novel product candidates that are comprised of multiple EMMs engineered in distinct combinations and ratios to simultaneously impact multiple metabolic pathways to modify the root causes of various complex diseases and improve health.

About Axcella’s Ongoing Clinical Studies

Each of the company’s clinical studies to date are or have been conducted as non-investigational new drug application (IND) clinical studies under U.S. Food and Drug Administration regulations and guidance supporting research with food. These studies evaluate product candidates for safety, tolerability and effects on the normal structures and functions in humans, including in individuals with disease. They are not designed or intended to evaluate a product candidate’s ability to diagnose, cure, mitigate, treat or prevent a disease. If Axcella decides to further develop a product candidate as a potential therapeutic, as is the case with AXA1665 and AXA1125, any subsequent clinical studies will be conducted under an IND.

Internet Posting of Information

Axcella uses its website, , as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors & News” section. Accordingly, investors should monitor such portions of the company’s website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

About Axcella

Axcella is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. Additional muscle- and blood-related programs are in earlier-stage development. For more information, please visit .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the characteristics and development potential of the company’s EMM product candidates and the company’s characterization of the results from its clinical studies and future clinical trials, including for AXA1125, the company’s anticipated program milestones, including the design, status and timing of the planned Phase 2b clinical trial of AXA1125 in adult NASH, the subject and timing of the company’s planned interactions with the FDA, including the timing of IND submissions, and the potential of the company’s product candidates to impact health and/or disease, including AXA1125’s potential in NASH. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to the potential impact of COVID-19 on the company’s ability to conduct and complete its ongoing or planned clinical studies and IND-enabled clinical trials in a timely manner or at all due to patient or principal investigator recruitment or availability challenges, clinical trial site shutdowns or other interruptions and potential limitations on the quality, completeness and interpretability of data the company is able to collect in its clinical studies or IND-enabled clinical trials, other potential impacts of COVID-19 on business and financial results, including with respect to the ability to raise additional capital, make planned interactions and submissions to FDA or other regulatory authorities in a timely manner or at all and operational disruptions or delays, changes in law, regulations, or interpretations and enforcement of regulatory guidance, whether data readouts and/or FDA feedback support the company’s IND submission and clinical trial initiation plans and timing, whether and when, if at all, the company’s product candidates will receive approval from the FDA or other comparable regulatory authorities, and for which, if any, indications, past results from clinical studies not being representative of future results, and other risks identified in the company’s SEC filings, including Axcella’s Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings with the SEC. The company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Axcella disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The company explicitly disclaims any obligation to update any forward-looking statements.

EN
27/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Axcella Health

Andreas Argyrides ... (+2)
  • Andreas Argyrides
  • Liana Moussatos
Andreas Argyrides ... (+8)
  • Andreas Argyrides
  • David Nierengarten
  • Dennis Pak
  • Laura Chico
  • Liana Moussatos
  • Ritika Das
  • Robert Driscoll
  • Sam Ravina
O5Q OWENS CORNING INC
BLUE BLUEBIRD BIO INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
KPTI KARYOPHARM THERAPEUTICS
GERN GERON CORP.
FL FOOT LOCKER INC.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
VRNA VERONA PHARMA ADS
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
SURF SURFACE ONCOLOGY
UBX UNITY BIOTECHNOLOGY
AVRO AVROBIO
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
MGTA MAGENTA THERAPEUTICS
AX AXOS FINANCIAL INC.
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
HARP HARPOON THERAPEUTICS
ISEE IVERIC BIO
IMUX IMMUNIC INC
BCEL ATRECA
C TEST
AXLA AXCELLA HEALTH
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
KDNY CHINOOK THERAPEUTICS
PASG INC.
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
FRLN ADICET BIO INC
ITOS FREELINE THERAPEUTICS HOLDINGS ADS
INZY ITEOS THERAPEUTICS
CDAK INOZYME PHARMA
ZNTL CODIAK BIOSCIENCES
BEAM INC.
PRAX ZENTALIS PHARMACEUTICALS
COGT BEAM THERAPEUTICS
TVTX PRAXIS PRECISION MEDICINES
KNTE COGENT BIOSCIENCES INC
VRDN TRAVERE THERAPEUTICS INC
VOR KINNATE BIOPHARMA
DAWN VIRIDIAN THERAPEUTICS INC
ELEV VOR BIOPHARMA
FHTX DAY ONE BIOPHARMACEUTICALS INC
TNGX ELEVATION ONCOLOGY
LBPH FOGHORN THERAPEUTICS
THRX TANGO THERAPEUTICS
VERA INC
TSVT LONGBOARD PHARMACEUTICALS
IMPL THESEUS PHARMACEUTICALS
DSGN INC.
TCRR VERA THERAPEUTICS INC
ATXS 2SEVENTY BIO INC
RANI IMPEL NEUROPHARMA INC
AVTE DESIGN THERAPEUTICS INC
CMPX TCR2 THERAPEUTICS INC
KRTX ASTRIA THERAPEUTICS INC
FUSN RANI THERAPEUTICS HLDGS INC
VIGL AEROVATE THERAPEUTICS INC
EWTX COMPASS THERAPEUTICS
BOLD KARUNA THERAPEUTICS INC
FUSION PHARMACEUTICALS INC
VIGIL NEUROSCIENCE INC
EDGEWISE THERAPEUTICS INC
AUDENTES THERAPEUTICS
Andreas Argyrides ... (+2)
  • Andreas Argyrides
  • Liana Moussatos
Wedbush Research
  • Wedbush Research
W WAYFAIR INC.
2454 MEDIATEK INC.
VMW VMWARE INC. CLASS A
QRVO QORVO INC.
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SGMO SANGAMO THERAPEUTICS INC.
RGNX REGENXBIO INC.
QCOM QUALCOMM INC
PSTG PURE STORAGE INC. CLASS A
PCRX PACIRA BIOSCIENCES INC.
PB PROSPERITY BANCSHARES INC.(R)
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GERN GERON CORP.
EWBC EAST WEST BANCORP INC.
BPMC BLUEPRINT MEDICINES CORP.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
OSTK OVERSTOCK.COM INC.
SWKS SKYWORKS SOLUTIONS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
HPE HEWLETT PACKARD ENTERPRISE CO.
UTHR UNITED THERAPEUTICS CORPORATION
NTLA INTELLIA THERAPEUTICS INC.
MRSN MERSANA THERAPEUTICS
ROKU ROKU INC. CLASS A
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
RCUS ARCUS BIOSCIENCES
AVGO BROADCOM INC.
AX AXOS FINANCIAL INC.
YMAB Y-MABS THERAPEUTICS
IMUX IMMUNIC INC
DELL DELL TECHNOLOGIES INC CLASS C
AXLA AXCELLA HEALTH
SWTX SPRINGWORKS THERAPEUTICS
SMCI SUPER MICRO COMPUTER
AQST INC.
KDNY AQUESTIVE THERAPEUTICS
BDTX CHINOOK THERAPEUTICS
COGT INC.
KNTE BLACK DIAMOND THERAPEUTICS
CYT COGENT BIOSCIENCES INC
TNGX KINNATE BIOPHARMA
THRX CYTEIR THERAPEUTICS
MRVL INC
STX TANGO THERAPEUTICS
GFS INC
THESEUS PHARMACEUTICALS
INC.
MARVELL TECHNOLOGY INC
SEAGATE TECHNOLOGY HLDGS PLC
GLOBALFOUNDRIES INC

ResearchPool Subscriptions

Get the most out of your insights

Get in touch